Trial Profile

Lomecel-B Effects on Alzheimer's Disease: A Randomized, Double-Blinded, Placebo-Controlled Phase 2a Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Jun 2026 According to Longeveron media release, company announced that additional analysis of data from the Phase 2a clinical trial evaluating its stem cell therapy laromestrocel in mild Alzheimers disease has been accepted for Poster Presentation at the 2026 Alzheimers Association International Conference (AAIC), to be held July 12-15, 2026 in London, United Kingdom and online.
01 Dec 2025 According to Longeveron media release, data from the trial were presented at the 18th Clinical Trials on Alzheimers Disease Conference (CTAD 2025).
01 Dec 2025 Results presented in the Longeveron Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com